Sparks commentary - Cantargia

Healthcare

Sparks - Cantargia

More on this equity
Cantargia (OMX: CANTA) granted new US patent
Published by Arron Aatkar, PhD

Cantargia has announced that the US Patent and Trademark Office has granted the patent related to its lead candidate, nadunolimab. The patent covers the use of nadunolimab as a potential medicine in combination with chemotherapy and/or immunotherapy. We note that the lead indication being targeted is pancreatic ductal adenocarcinoma in combination with chemotherapy; this will be protected by the new patent. The patent is valid until 2035, excluding any potential extensions.

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free